Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.

Frontiers in immunology - 1 Jan 2022

Liu Chao, Xiao Huiting, Cui Luying, Fang Lin, Han Shuling, Ruan Yuli, Zhao Wenyuan, Zhang Yanqiao

Abstract excerpt

Background: Combination therapy with immune checkpoint inhibitors (ICIs) may benefit approximately 10-20% of microsatellite-stable colorectal cancer (MSS-CRC) patients. However, there is a lack of optimal biomarkers. This study aims to understand the predictive value of epigenetic-related gene mutations in ICIs therapy in MSS-CRC patients. Methods: We analyzed DNA sequences and gene expression profiles from The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36479108
DOI: 10.3389/fimmu.2022.1039631
PMCID: PMC9720302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.PMID 36479108Read ↗

Epigenetics and immunotherapy in colorectal cancer: progress and promiseSemantic proximity Read ↗

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal CancerSemantic proximity Read ↗

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives.Semantic proximity Read ↗

Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.Semantic proximity Read ↗

The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancerSemantic proximity Read ↗

Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancerSemantic proximity Read ↗

Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancerSemantic proximity Read ↗

Epigenetic Mechanisms of Resistance to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.Semantic proximity Read ↗

Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatmentSemantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.